Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Actinium Pharmaceuticals  / Equity Bottom-Up

<ul><li>Actinium Pharmaceuticals is a biology-driven radiotherapy company advancing candidates in oncology and conditioning for solid tumors and hematological malignancies.</li><li>Its approach is expanding the reach of radiopharmaceuticals to novel target-isotope combinations in acute myeloid leukemia, solid tumors & conditioning.</li><li>It favors Ac-225 isotopes in its oncology pipeline and I-131 for conditioning candidates.</li></ul>

Actinium Pharmaceuticals is a biology-driven radiotherapy company advancing candidates in oncology and conditioning for solid tumors and hematological malignancies.Its approach is expanding the reach of radiopharmaceuticals to novel target-isotope combinations in acute myeloid leukemia, solid tumors & conditioning.It favors Ac-225 isotopes in its oncology pipeline and I-131 for conditioning candidates.

ATNM: Initiating Coverage - Diversified Nuclear Medicine Portfolio

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Actinium's lead candidate, Iomab-B, faced a significant setback in August 2024 when the FDA determined the Phase 3 SIERRA trial data was insufficient for a Biologics License Application (BLA) filing, requiring a new trial to demonstrate overall survival.</li>
  <li>The company is now prioritizing its Actinium-225 based pipeline, including Actimab-A for Acute Myeloid Leukemia (AML) and ATNM-400 for solid tumors, which leverages the potent alpha-emitting isotope.</li>
  <li>As a clinical-stage biopharmaceutical, Actinium remains pre-revenue with significant net losses and cash burn, making it dependent on capital markets or strategic partnerships to fund future development and a potential new trial for Iomab-B.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Actinium's lead candidate, Iomab-B, faced a significant setback in August 2024 when the FDA determined the Phase 3 SIERRA trial data was insufficient for a Biologics License Application (BLA) filing, requiring a new trial to demonstrate overall survival.
  The company is now prioritizing its Actinium-225 based pipeline, including Actimab-A for Acute Myeloid Leukemia (AML) and ATNM-400 for solid tumors, which leverages the potent alpha-emitting isotope.
  As a clinical-stage biopharmaceutical, Actinium remains pre-revenue with significant net losses and cash burn, making it dependent on capital markets or strategic partnerships to fund future development and a potential new trial for Iomab-B.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Actinium Pharmaceuticals  (ATNM US) - Aug 2026

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li><li>Last week, ALDX completed the additional study needed to resubmit dry eye NDA.</li><li>Kidney disease drugs continue to benefit from regulatory tailwinds, as NVS gained IgAN approval and APLS succeeded in a pivotal biomarker study in C3G/IC- MPGN.</li></ul>

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.Last week, ALDX completed the additional study needed to resubmit dry eye NDA.Kidney disease drugs continue to benefit from regulatory tailwinds, as NVS gained IgAN approval and APLS succeeded in a pivotal biomarker study in C3G/IC- MPGN.

Biopharma Week in Review - August 12, 2024

United States

Actinium Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops pipeline of antibody radiation conjugates for targeted conditioning and combination therapies. Actinium Pharmaceuticals serves clients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Actinium Pharmaceuticals (ATNM US)

ATNM: Initiating Coverage - Diversified Nuclear Medicine Portfolio

Actinium Pharmaceuticals is a biology-driven radiotherapy company advancing candidates in oncology and conditioning for solid tumors and...

Zacks Small Cap Research

Primer: Actinium Pharmaceuticals (ATNM US) - Aug 2026

Actinium's lead candidate, Iomab-B, faced a significant setback in August 2024 when the FDA determined the Phase 3 SIERRA trial data was...

αSK Primers

Biopharma Week in Review - August 12, 2024

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A.

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)